Press Releases Krystal Biotech, Inc.

Equities

KRYS

US5011471027

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-17 pm EDT			5-day change	1st Jan Change
164.1 ^USD	+0.20%		+6.04%	+32.27%

May. 14	Transcript : Krystal Biotech, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 02:20 PM
May. 06	Sector Update: Health Care Stocks Gain Pre-Bell Monday	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Krystal Biotech to Present at the American Thoracic Society 2024 International Conference	May. 15	AQ
Krystal Biotech to Present at BofA Securities 2024 Health Care Conference	May. 08	AQ
Krystal Biotech Announces First Quarter 2024 Financial Results and Provides Business Updates	May. 06	AQ
Krystal Biotech to Present at the Association for Research in Vision and Ophthalmology 2024 Annual Meeting	May. 02	AQ
Krystal Biotech to Report First Quarter 2024 Financial Results on May 6, 2024	Apr. 26	AQ
Krystal Biotech Announces First Patient Dosed in Phase 1 Clinical Trial of Inhaled KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors of the Lung	Apr. 22	AQ
Krystal Biotech to Present at the American Association for Cancer Research 2024 Annual Meeting	Apr. 05	AQ
Krystal Biotech to Present at the American Association for Cancer Research 2024 Annual Meeting	Apr. 04	AQ
Krystal Biotech to Present at TD Cowen 44th Annual Health Care Conference	Feb. 29	AQ
Krystal Biotech to Present at TD Cowen 44th Annual Health Care Conference	Feb. 28	AQ
Krystal Biotech Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates	Feb. 26	AQ
Krystal Biotech to Report Fourth Quarter and Full Year 2023 Financial Results on February 26, 2024	Feb. 21	AQ
Krystal Biotech to Report Fourth Quarter and Full Year 2023 Financial Results on February 26, 2024	Feb. 20	AQ
Cystic Fibrosis Pipeline Insights Report 2024 \| Krystal Biotech, Vertex Pharmaceuticals, Translate Bio, Novartis, and others.	Feb. 19	AQ
Krystal Biotech Receives FDA Fast Track Designation for Inhaled Oncology Candidate KB707 to Treat Solid Tumors of the Lung	Feb. 13	AQ
Krystal Biotech Announces Publication in the New England Journal of Medicine on the Application of B-VEC to Treat Ocular Complications in Patient with Dystrophic Epidermolysis Bullosa	Feb. 08	AQ
Krystal Biotech to Present at Guggenheim 6th Annual Biotechnology Conference	Feb. 01	AQ
Krystal Biotech Receives Permanent J-code (J3401) for VYJUVEK®	Jan. 04	AQ
Krystal Biotech Receives Orphan Drug Designation from the Japanese MHLW for Beremagene Geperpavec-svdt	Dec. 20	AQ
Krystal Biotech Receives Orphan Drug Designation from the Japanese MHLW for Beremagene Geperpavec-svdt (B-VEC)	Dec. 19	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Krystal Biotech, Inc.

Equities

KRYS

US5011471027

Press Releases

Filters